Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
about
New insights into treatment of osteoporosis in postmenopausal womenEfficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-AnalysisUpdate on denosumab in the management of postmenopausal osteoporosis: patient preference and adherenceA Review of Patient Preferences for Osteoporosis Drug TreatmentA review of denosumab for the treatment of osteoporosisDenosumab for the treatment of osteoporosisObservations following discontinuation of long-term denosumab therapy.Screening, assessment, and treatment of osteoporosis for the nurse practitioner: key questions and answers for clinical practice--a Canadian perspectiveInterventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in SpainPersistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional studyPersistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysisDenosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer PerspectiveBisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review.Health technology assessment in osteoporosis.Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United StatesOsteoporosis in men: epidemiology and treatment with denosumab.Skeletal and extraskeletal actions of denosumab.Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic women.Denosumab in osteoporosis.The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.Denosumab: a review of its use in postmenopausal women with osteoporosis.Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.Treatment of osteoporosis after alendronate or risedronate.One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.Using Osteoporosis Therapies in Combination.Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis.Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
P2860
Q26777910-2762ABAD-CD1D-4460-8278-6182C3D095D6Q26778216-3871C923-B242-486F-A61F-B10FE20B894CQ26778291-2F9FA03A-03B0-4952-B177-48C0DD2B62E1Q26796811-08622C2E-32BF-4AB4-8E22-3EB00BC06A96Q27005894-807D3B18-BA0D-4043-9567-0969970EFF74Q27009275-3B1037A9-BE3D-40C4-910C-1EB327CBD531Q33563846-C57B377C-A78F-416B-9DF8-9CAC560CDA8EQ34074981-66031C7F-348E-4292-B1F0-8FE197B299FAQ34699332-5F02091A-285E-46D0-82F6-2982EE96E51BQ34863304-84E44498-83C8-49E4-A457-E798688B875FQ35087883-38BDEE3A-0F2E-4669-8F8C-C3619DA48DD4Q36073613-E0B00346-E1E0-40DA-B85E-65C5FEDEFD76Q36073645-489EA000-5168-4924-9FD7-7F13853E66CFQ36400967-5B888C7A-7633-4B04-8D16-332CB1618DC8Q36523054-3F6FCCF1-7A1B-4A8B-9060-BAD67184BF73Q36529793-293BEECA-F263-49ED-A821-4BAE907A2329Q36965411-820F5319-57D5-40AC-B333-E0BD65D51DC6Q37147488-FB672EB4-E967-4FF5-A5A4-04599F24CFA4Q37192904-9C808E56-B5FE-40F0-822C-9FBB3EA36350Q37298020-D7BE68FC-B826-441F-868F-DC32EFD0EB64Q37340602-CD93F2A7-3D1D-40A9-BFA4-C1D96725FC48Q37670574-DE2ABF7B-1BA9-4904-9C4A-51E7B86B29C9Q37702188-538ED09F-9436-4086-933F-1AA6090E71F5Q38009712-266306DA-82C2-4A97-BB2A-00B7EEC63624Q38080911-0FC45C21-A7B9-45A6-9DE0-4986E09C3C57Q38167352-E50B35A0-4AA3-45A4-9868-46D36B25CD5EQ38193181-8D8B1560-7BC7-4D87-94CF-BA50901CCA22Q38220743-B9FB4B10-5AB8-4C0F-AEDE-639F316DE94EQ38339579-EBE77302-E944-4D8C-9DC3-491CE48004AFQ38599682-700A3E50-9795-46ED-B874-AB212FD1E191Q38676331-E57C04A4-C0B9-4DF5-9CA8-D238DD30965CQ38712724-7173F8AE-1AEE-457C-9249-EC025DBB7154Q38793382-D4030171-C7C5-41E4-AB2A-25DBF3B3FDE1Q38819059-320C1D1D-ED4B-4C27-A05C-AEACA67BCFD0Q39408210-CB386D4B-D6A4-47E9-83EB-E9BB3D9DEB4FQ39888072-60409ECF-94E3-41C3-9057-38E1C8DAAC3CQ40437923-F164EC05-BA2B-4005-A25E-0D7701BA6F19Q40688871-D55F50B2-2916-4D8D-93D5-34155616FFB8Q44065014-EAAE9310-533A-43D9-8AE5-916DDD91EE12Q46899289-8FBAE114-E9E9-406D-B555-8FDDD405D9EA
P2860
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Final results of the DAPS (Den ...... onate in postmenopausal women.
@ast
Final results of the DAPS (Den ...... onate in postmenopausal women.
@en
type
label
Final results of the DAPS (Den ...... onate in postmenopausal women.
@ast
Final results of the DAPS (Den ...... onate in postmenopausal women.
@en
prefLabel
Final results of the DAPS (Den ...... onate in postmenopausal women.
@ast
Final results of the DAPS (Den ...... onate in postmenopausal women.
@en
P2093
P2860
P1476
Final results of the DAPS (Den ...... onate in postmenopausal women.
@en
P2093
D Macarios
DAPS Investigators
J Borenstein
N Freemantle
S Satram-Hoang
S Siddhanti
P2860
P2888
P304
P356
10.1007/S00198-011-1780-1
P407
P577
2011-09-17T00:00:00Z